400770-90-3

Basic information

• Product Name: tert‐butyl‐4‐fluoro‐4‐phenylpiperidine‐1‐carboxylate
• Synonyms: tert‐butyl‐4‐fluoro‐4‐phenylpiperidine‐1‐carboxylate
• CAS NO: 400770-90-3
• Molecular Weight: 279.355
• Mol File: 400770-90-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: tert‐butyl‐4‐fluoro‐4‐phenylpiperidine‐1‐carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: tert‐butyl‐4‐fluoro‐4‐phenylpiperidine‐1‐carboxylate(400770-90-3)
• EPA Substance Registry System: tert‐butyl‐4‐fluoro‐4‐phenylpiperidine‐1‐carboxylate(400770-90-3)

Safety Data

• Hazardous Substances Data: 400770-90-3(Hazardous Substances Data)

Upstream product

• 40807-61-2 4-hydroxy-4-phenylpiperidin 
• 24424-99-5 di-tert-butyl dicarbonate 
• 160376-88-5 tert-butyl 4-acetyl-4-phenylpiperidine-1-carboxylate 
• 172734-33-7 4-hydroxy-4-phenylpiperidine-1-carboxylic acid tert-butyl ester 

Downstream Products

• 400770-91-4 4‐fluoro‐4‐phenylpiperidine 
• 1056382-25-2 4-fluoro-4-phenylpiperidine hydrochloride 

Relevant articles and documents

Propafenone analogue with additional H-bond acceptor group shows increased inhibitory activity on P-glycoprotein

P-glycoprotein (P-gp) is an ATP-dependent efflux pump that has a marked impact on the absorption, distribution, and excretion of therapeutic drugs. As P-gp inhibition can result in drug–drug interactions and altered drug bioavailability, identifying molec

1',3'-DISUBSTITUTED-4-PHENYL-3,4,5,6-TETRAHYDRO-2H, 1'H-[1, 4'] BIPYRIDINYL-2'-ONES

The present invention relates to novel compounds, in particular novel pyridinone derivatives according to Formula (I) wherein all radicals are as defined in the application and claims. The compounds according to the invention are positive allosteric modulators of metabotropic receptors - subtype 2 ("mGluR2") which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. In particular, such diseases are central nervous system disorders selected from the group of anxiety, schizophrenia, migraine, depression, and epilepsy. The invention is also directed to pharmaceutical compositions and processes to prepare such compounds and compositions, as well as to the use of such compounds for the prevention and treatment of such diseases in which mGluR2 is involved.

Acetamides and benzamides that are useful in treating sexual dysfunction

The present invention relates to the use of compounds of formula (I) for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.